SYRE Spyre Therapeutics, Inc.
$90.60▲ +2.13%
Healthcare
Other
After hours
$90.60▲ +0.00%
Sep 11, 7:30 PM ET
Volume 886.1K
Avg Volume (10D) 1.22M
Key Metrics & Fundamentals
Market Cap
$7.99B
P/E Ratio
–
Div Yield
–%
52W Range
14.51 - 110.18
% vs 50 MA
-7.65%
% vs 200 MA
43.15%
RSI-14
42.8
MACD Histogram
-0.8500
Beta (1Y vs SPY)
1.87
Free Cash Flow
-$69.88M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$121.64M
COGS
–
Operating Exp
$81.64M
Operating Income
-$81.64M
EBIT
-$81.64M
Pretax Income
-$36.20M
Net Income
-$36.20M
EPS (Diluted)
-0.43
Price & Volume History
Loading chart…
Recent News
Spyre Therapeutics (SYRE) Reports SPY003 Endoscopic Improvement. Can Randomized Testing Confirm It?
Insider Monkey · Sep 10, 2026 11:59 PM
Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study
Zacks · Sep 9, 2026 1:56 PM
Spyre Therapeutics' SPY003 Meets Phase 2 Primary Endpoint in Ulcerative Colitis
MT Newswires · Sep 8, 2026 1:35 PM
Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations
GlobeNewswire · Sep 8, 2026 12:00 PM
Spyre Therapeutics Announces Grants of Inducement Awards
GlobeNewswire · Sep 4, 2026 8:01 PM
Spyre Therapeutics Insider Sold Shares Worth $2,480,529, According to a Recent SEC Filing
MT Newswires · Sep 4, 2026 7:41 AM
Spyre Therapeutics Insider Sold Shares Worth $2,283,821, According to a Recent SEC Filing
MT Newswires · Sep 4, 2026 7:30 AM
Spyre Therapeutics Insider Sold Shares Worth $1,309,410, According to a Recent SEC Filing
MT Newswires · Sep 4, 2026 7:30 AM
Spyre Therapeutics to Participate in Upcoming September Investor Conferences
GlobeNewswire · Sep 3, 2026 8:05 PM
Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound?
Zacks · Sep 3, 2026 3:30 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See SYRE's money flow as a full page
Social Sentiment
No Reddit posts found for SYRE.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.